FDA Panel Reluctantly Backs Patisiran for ATTR Cardiomyopathy
FDA advisors conceded on Wednesday that the benefit-risk balance of patisiran (Onpattro) technically checks out in wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM, also known as cardiac ATTR amyloidosis) — though they were unconvinced that the benefits are actually meaningful. At the end of the day, the Cardiovascular and Renal Drugs Advisory Committee ultimately voted […]